These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36794307)

  • 1. Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases.
    Gosselt HR; van Lint JA; Kosse LJ; Spuls PI; Vonkeman HE; Tas SW; Hoentjen F; Nurmohamed MT; van den Bemt BJF; van Doorn MBA; Jessurun NT
    Expert Opin Drug Saf; 2023; 22(6):501-507. PubMed ID: 36794307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.
    Roest LH; Kosse LJ; van Lint JA; Gosselt HR; Scholl JHG; van Puijenbroek E; Vonkeman HE; Tas SW; Nurmohamed MT; van den Bemt BJF; Jessurun NT
    Expert Opin Drug Saf; 2023 Mar; 22(3):203-211. PubMed ID: 36036179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.
    van Lint JA; Jessurun NT; Hebing RCF; Hoentjen F; Tas SW; Vonkeman HE; van Doorn MBA; Sobels A; Spuls PI; van Puijenbroek EP; Nurmohamed MT; van den Bemt BJF
    Drug Saf; 2020 Sep; 43(9):917-925. PubMed ID: 32451974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
    Velthuis K; Jessurun NT; Nguyen TDM; Scholl J; Jansen JRG; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE
    Expert Opin Drug Saf; 2023; 22(6):485-492. PubMed ID: 36683590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.
    van Lint JA; Jessurun NT; Tas SW; van den Bemt BJF; Nurmohamed MT; van Doorn MBA; Spuls PI; van Tubergen AM; Ten Klooster PM; van Puijenbroek EP; Hoentjen F; Vonkeman HE
    J Rheumatol; 2021 Sep; 48(9):1388-1394. PubMed ID: 33993115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics.
    Kosse LJ; Weits G; Vonkeman HE; Spuls PI; Van Den Bemt BJF; Tas SW; Hoentjen F; Nurmohamed MT; Van Doorn MBA; Van Puijenbroek EP; Jessurun NT
    Expert Opin Drug Saf; 2020 Aug; 19(8):1049-1054. PubMed ID: 32524887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
    Thomas PWA; Römkens TEH; West RL; Russel MGVM; Jansen JM; van Lint JA; Jessurun NT; Hoentjen F
    United European Gastroenterol J; 2021 Oct; 9(8):919-928. PubMed ID: 34077634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor.
    van Lint JA; Jessurun NT; Tas SW; Vonkeman HE; van Doorn MBA; Hoentjen F; Nurmohamed MT; van Puijenbroek EP; van den Bemt BJF
    BioDrugs; 2023 Jul; 37(4):541-550. PubMed ID: 37010772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database.
    Maity T; Longo C
    BMC Health Serv Res; 2021 Nov; 21(1):1231. PubMed ID: 34774053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study.
    König BH; Gosselt HR; van Lint JA; Kosse LJ; van den Bemt BJF; Ten Klooster PM; Vonkeman HE; Jessurun NT
    Expert Opin Drug Saf; 2024 Aug; ():1-6. PubMed ID: 39041288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.
    Giraud EL; Jessurun NT; van Hunsel FPAM; van Puijenbroek EP; van Tubergen A; Ten Klooster PM; Vonkeman HE
    Expert Opin Drug Saf; 2020 Dec; 19(12):1617-1624. PubMed ID: 32990050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.
    Dubrall D; Leitzen S; Toni I; Stingl J; Schulz M; Schmid M; Neubert A; Sachs B
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):56. PubMed ID: 34620231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
    Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
    J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab.
    Smith K; Golder S; Sarker A; Loke Y; O'Connor K; Gonzalez-Hernandez G
    Drug Saf; 2018 Dec; 41(12):1397-1410. PubMed ID: 30167992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.
    de Camargo MC; Barros BCA; Fulone I; Silva MT; Silveira MSDN; de Camargo IA; Barberato-Filho S; Del Fiol FS; Lopes LC
    Front Pharmacol; 2019; 10():965. PubMed ID: 31572173
    [No Abstract]   [Full Text] [Related]  

  • 19. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.
    Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK
    BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The importance of patient perspective in drug surveillance systems].
    Gäwert L; Hierse F; Zink A; Strangfeld A
    Z Rheumatol; 2010 Nov; 69(9):795-802. PubMed ID: 21063828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.